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Neglected Tropical Diseases (NTDs) affect an estimated 1 billion people in 149 countries. The World Health
Organization (WHO) prioritised 17 NTDs for control and elimination by 2020 and deﬁned a Road Map to help
countries reach these goals. Improved diagnostics for NTDs are essential for guiding treatment strategies at
different thresholds of control, interruption of transmission, elimination and post-elimination surveillance.
While substantial progress has been made in the last decade with chemotherapy, the same cannot be said of
diagnostics, largely due to the perceived lack of a commercially viable market for NTD diagnostics.
New sample in-answer out nucleic acid ampliﬁcation technologies that can be performed at the point-of-care
offer improved performance over current technologies and the potential to test for multiple pathogens using a
single specimen. Finding commonalities for different NTDs in terms of geographic overlap, sentinel populations
and treatment strategy will allow NTD programs to leverage these innovations to build cost-effective multiplex
surveillance platforms. Connectivity solutions linking data from diagnostic laboratories and POC test readers/
devices provide opportunities for automated surveillance systems to make health systems more efﬁcient,
improving patient outcomes and assessing impact of interventions in real time. New models of public–private
product development partnerships are critical in leveraging diagnostic innovation in other priority area for better
diagnosis, control and elimination of NTDs.
© 2017 Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords:
Neglected tropical diseases
Diagnostics
Control
Elimination
Surveillance
1. Introduction
Neglected Tropical Diseases (NTDs) affect an estimated 1 billion
people in 149 countries in the developing world and give rise to a
myriad of adverse impacts, including anemia, blindness, cognitive
impairment, and death [1,2]. The World Health Organization (WHO)
prioritised 17 NTDs (Buruli ulcer, Chagas disease, cysticercosis, Dengue,
drancunculiasis (Guinea worm disease), echinococcosis, endemic trep-
onematoses (Yaws), foodborne trematode infections, human African
trypanosomiasis (HAT), visceral leishmaniasis (VL), leprosy, lymphatic
ﬁlariasis (LF), onchocerciasis, rabies, schistosomiasis, soil-transmitted
helminthiases (STH), and trachoma) for control and elimination.
These NTDs were selected on the basis that their transmission charac-
teristics or treatment opportunities make them good candidates for
control and elimination [3].
WHO, the Bill & Melinda Gates Foundation and 13 leading pharma-
ceutical companies, at a meeting in London in 2010, resolved to sustain,
expand and extend programmes to ensure the necessary supply of
drugs and other interventions to eradicate Guinea worm disease,
eliminate LF, leprosy, HAT and blinding trachoma; and to control
schistosomiasis, STH, Chagas disease, VL and onchocerciasis by 2020
[4]. The London Declaration ensured the donation of drugs for NTDs
but diagnostics, critically needed for monitoring progress towards
elimination and assessing the impact of special intervention, was not
included in the Declaration as a priority.
In 2013, WHO deﬁned a Road Map including ﬁve key interventions
to help countries reach the 2020 goals [3]. These are: (i) preventive che-
motherapy based on large-scale use of safe, single-dose medicines at
regular intervals (i.e. mass drug administration, MDA); (ii) innovative
and intensive case management; (iii) vector ecology and management;
(iv) improvements in water, sanitation and hygiene in NTD-endemic
areas; and (v) veterinary interventions to protect and improve human
health [2,3]. While substantial progress has been made in the last
decade with chemotherapy reaching a billion people in 2014 [5], the
same cannot be said of diagnostics needed to guide chemotherapy and
for surveillance, largely due to the perceived lack of a commercially
viable market for NTD diagnostics.
Diagnostics are needed,with the exception of Guineawormwhich is
associated with unmistakable clinical features, to monitor and certify
elimination of NTDs. Dowdle advocated for ‘practical diagnostic tools
of sufﬁcient sensitivity and speciﬁcity to detect levels of infection that
can lead to transmission’ as an essential requirement for disease elimi-
nation or eradication [6]. The lack of a clear diagnostic strategy has
resulted in limited surveillance data, with countries often using only
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using disease burden as a proxy for countrywide data. Solomon et al.
suggested that country programs for control and elimination of NTDs
demand improved diagnostic tools in order to “guide decisions on the
required intensity, frequency, and duration of intervention and to con-
duct surveillance for re-emergency of infection after elimination” [7].
This article examines recent advances in diagnostic technologies
driven by high proﬁle, high burden diseases such as HIV and tuberculo-
sis, emerging global health threats such as antimicrobial resistance
and emergencies such as outbreaks of SARS, Ebola virus disease and
Zika virus infections, and determines how these innovations can be
leveraged to improve the diagnosis and surveillance of NTDs.
2. Investments in diagnostic innovation
Accurate diagnostic tests are commercially available for most infec-
tious diseases. These tests are laboratory based and hence not widely
accessible in the developing world, where laboratory infra-structure is
often limited. The need for increasing access to diagnostics for patients
withHIV and TB in thedevelopmentworld has led tomajor investments
inmore accessible diagnostic technologies that can be used at the point-
of-care within the last decade.
2.1. Diagnostic innovations for HIV and tuberculosis
UNAIDS set 90–90–90 targets for HIV which call for 90% of those
who are infected know their HIV status, 90% of those infected be put
on treatment, and 90% of those on treatment achieve viral suppression
[8]. Globally, countries are now at 50%, 37% and 25% respectively with
regard to these targets [9]. To realize these targets, good performing
diagnostic and monitoring tests that are widely accessible for popula-
tions in remote areas or marginalized from care are needed.
The diagnosis of TB traditionally depends on smear microscopy
and chest radiography, both of which are insufﬁciently sensitive and
speciﬁc. Culture is highly speciﬁc but requires up to 6weeks for a result.
Molecular methods are now used in developed countries, but the cost
and requirement for laboratory infrastructure and skilled technical
staff prevent their adoption in low-resource settings. Modeling studies
show that if a test of 85% sensitivity and 97% speciﬁcity can be per-
formed during a single patient visit and is widely implemented,
625,000 lives could be saved each year [10,11].
Investments in point-of-care (POC) technologies have resulted in a
range of highly sensitive and speciﬁc HIV and TB molecular assays
that can be performed in remote settings [12]. These tests are designed
in a “sample-in answer-out” format, requiring minimal training, and
providing a result in 1–2 h. Molecular platforms which can detect
Mycobacterium tuberculosis and rifampicin resistancewith high accuracy
in just under 2 h have transformed TB diagnosis in both the developed
and developing world. POC tests for CD4 enumeration have been com-
mercially available for a few years now and have shortened delay in
HIV treatment [13]. POC assays for HIV early infant diagnosis and viral
load are currently under evaluation and will be implemented shortly.
The expectations are that these tests will increase access to HIV viral
load monitoring and early infant diagnosis with faster turn-around
time for results to patients, increased linkage to care and reduced loss-
to-follow up, and decreased risk of drug resistance.
2.2. Diagnostics for global health emergencies
Further investments in technological innovation are being driven by
successive global health emergencies including SARS, ﬂu, MERS CoV,
Ebola virus disease and Zika virus infection. WHO calls for development
of open platform technologies to accelerate the development, validation
and production of vaccines, therapeutics, diagnostics and reagents for
infectious diseases of epidemic potential as part of the WHO Blue Print
for R&D preparedness [14]. At the 2015 G7Ministers of Health meeting,
there was consensus on “…continued ﬁnancing, collaboration and
coordination… through initiatives such as the WHO blueprint for R&D
preparedness and the Global Research Collaboration for Infectious
Disease Preparedness (GloPID-R)” [15].
The priority pathogens for theWHOBlue Print R&D include Crimean
Congo Haemorrhagic Fever (CCHF), Filoviruses, Lassa, Severe
Coronaviruses such as the Corona viruses that caused SARS and the
Middle East Respiratory Syndrome (MERS CoV), Nipah virus, Rift Valley
fever, Chikungunya, Zika and Severe fever with Thrombocytopenia
Syndrome (SFTS), an emerging tick-borne infectious disease caused by
the SFTS virus (SFTSV), a novel and highly pathogenic phlebovirus in
the family Bunyaviridae. As a result of the call for open platform
technologies, industry and public sector developers have initiated col-
laborations to work together to accelerate product development.
These open platform technologies are being developed by compa-
nies that have already developed highly accurate POC tests for HIV
and TB. Many of these companies have also developed cartridges to
detect Ebola and Zika viruses using the same platform. Some companies
have already developed a broadmenuof infectious diseases on the same
platform. Advocacy and incentives, such as advance market commit-
ment, would be needed for these companies to apply their technologies
to NTDs. A review of emerging molecular technologies that have
been developed and can be used in resource-limited settings has been
published [16].
2.3. Antimicrobial resistance
Antimicrobial resistance (AMR) is one of the greatest public health
challenges of this century with an estimated 25,000 deaths and over
€1.5 billion a year in healthcare expenses and productivity losses in
Europe alone [17–19]. In the United Kingdom AMR Strategy, two of
the ﬁve AMR targets require the development of diagnostics that will
rapidly identify infections that require antibiotics and of assays that
can be used to identify and track patterns of antimicrobial resistance
[18]. Rapid POC tests can also be used in drug trials to reduce the cost
and length of trials, as target populations can be identiﬁed and recruited
without expensive laboratory tests and procedures. Diagnostic technol-
ogies for AMR currently available and in the pipeline are described in
a compendium prepared by the Oxford Centre for Evidence-based
Medicine [20].
The challenge is to create a cost-effective, accurate, rapid, and easy-
to-use test for bacterial infections that will allow health professionals
worldwide to administer the right antibiotics at the right time or rule
out antibiotic use by identifying viral infections. A number of initiatives
to incentivise public and private sectors to develop rapid diagnostic
tests and assays for AMR surveillance have been announced. The
£10 million Longitude Prize is a prize fund for a diagnostic tool that
can be used to rule out antibiotic use or help identify an effective
antibiotic to treat a patient [21]. The Horizon 2020 prize of €1 million
put forth by the European Commission is to incentivise better use of
antibiotics for respiratory infections through the development of a
rapid test that will allow healthcare providers to distinguish, at the
point of care, between patients with respiratory tract infections that
require antibiotics and those who can be managed safely without
antibiotics [22]. The US National Institutes of Health has also offered a
prize of up to $20 million to the ﬁrst group(s) to develop a rapid, POC
diagnostic test to be used by health care providers to identify highly
resistant bacterial infections to promote responsible use of antibiotics
[23].
Promising high throughput array technologies for pathogen detec-
tion coupled with detection of antimicrobial susceptibility patterns for
AMR surveillance will be needed to guide patient management and
improve our understanding of the emergence and spread of resistance.
How can the NTD community leverage these investments in diagnostic
innovation to improve patient management, disease control and
surveillance towards the elimination of NTDs?
272 R.W. Peeling et al. / Computational and Structural Biotechnology Journal 15 (2017) 271–274
3. Innovation in diagnostics for NTDs
It is neither feasible nor efﬁcient for countries tomanage 17 NTDs as
individual vertical programmes, each with its own range of diagnostic
and surveillance tools. There is a need to ﬁnd commonalities and
develop a unifying strategy for the diagnosis and surveillance of NTDs.
Commonalities that can be considered are:
3.1. NTDswith a common control strategy such asmass drug administration
Different types of diagnostics are needed to inform policy decisions
at different stages of control for NTDs forwhichMDA is themain control
strategy [24]. Aftermultiple rounds ofMDA, highly sensitive and speciﬁc
diagnostics are needed to locate “hot spots” of residual infection. For
schistosomiasis, the intensity of transmission decreaseswith decreasing
prevalence of infection. Microscopy is no longer sufﬁciently sensitive
to detect residual infection in communities when the number of
eggs per gram of stool falls below 40. Antigen or nucleic acid ampliﬁed
tests (NAATs) are needed to replace microscopy to identify communi-
ties in which transmission is still occurring. However, most antigen
detection tests using enzyme immunoassays or lateral ﬂow tests
have not been shown to be sufﬁciently sensitive and current NAATs
are too expensive and technical demanding for community based
screening. As NAATs become available in POC format and have data
transmission capabilities, these devices can be taken around to different
communities to determine the stage of control and to inform treatment
strategies.
3.2. Overlapping geographic endemicity and common sentinel populations
Muchprogress has beenmade inmapping the geographical distribu-
tion of different NTDs. In areas with overlapping NTDs, if the sentinel
population is similar, there could be cost saving and efﬁciencies in
collecting a single specimen for surveillance of multiple NTDs. For LF,
trachoma, schistosomiasis, onchocerciasis, the sentinel population is
children under ten years of age. Multiplex antibody detection assays
that can be performed on a single dried blood spot from ﬁnger pricked
blood offer the most cost-effective means of surveillance [7].
3.3. Common treatment
Both Yaws and trachoma require community based treatment with
one or more rounds of mass treatment with azithromycin. Although
the goals of the yaws and trachoma programs are different, and the
implementation of interventions may not be fully aligned, there may
be potential synergies between the two programs in the use of duplex
diagnostic tests for case ﬁnding and surveillance [25].
3.4. Advances in diagnosis of viral infections
The diagnosis of viral infections is traditionallymade by demonstrat-
ing a seroconversion to IgM or a 4-fold rise in IgG titers between acute
and convalescent sera taken more than 10 days apart. Such paired
sera are difﬁcult to obtain. Hunsperger et al. showed recently that
N90% of dengue cases can be diagnosed from a single serum specimen
collected during the ﬁrst 10 days of illness by testing it with either
DENV-RT-PCR + IgM ELISA or NS1 antigen ELISA + IgM ELISA [26].
This opens up an exciting possibility of using test combinations to
diagnose viral NTDs with a single blood sample taken during the acute
phase of infection. It offers a tremendous improvement over our current
struggles with global health emergencies most of which are caused by
outbreaks of viral diseases.
4. The promise of connectivity to strengthen the efﬁciency of health
systems
In 2001 Heymann and Rodier drew our attention to the capability of
‘infectious disease intelligence’ to improve early warning capacity for
potential worldwide public health problems and possibly diminish or
even prevent the spread of infectious diseases [27]. Connectivity solu-
tions for testing at the point-of-care can now be used to provide timely
information on testing, trends, quality assurance and can be coupled to
optimize supply chain management. Alerts can be built into connectiv-
ity systems to support disease surveillance and outbreak investigations.
Nowadays there are a lot of POC devices that can digitize data
and transmit them to a central database [28]. This integration of digital
technology into diagnosticswill allow theministry of health to have up-
to-the-hour information on what is happening across the country.
Connectivity solutions can also be used to link in proﬁciency testing
results from each testing site and alerts for remedial action with the
ultimate goal of improving the accuracy of testing across the country.
Supply chain management can be informed through links to the testing
database, which is another opportunity to strengthen the healthcare
system.
In some countries, bi-directional connectivity not only allows
healthcare sites to send information to the central database, but the
database can report trends back to the site operators. Information
about the devices can also be tracked, such as frequency of device failure
and error rates. More research is needed to understand middleware
solutions as to whether they could extract the same set of data from
different data clouds, what kind of IT knowledge would be needed to
manage such systems in the ﬁeld and what advice countries would
need about human resources and training. This would all make the
health system a lot more efﬁcient and the information would be very
useful for designing control programs, tracking disease trends and
assessing the impact of interventions in real time.
5. The challenges of implementing POC diagnostics
While POC tests can offer rapid identiﬁcation of the causes of
infections and enable appropriate prescribing, taking testing outside of
laboratories can add stresses to a weak or fragile health care system.
Leadership and infrastructure for critical decision making on the adop-
tion of new diagnostic technologies are often fragmented or absent in
many countries. Companies with novel diagnostic technologies often
face long delays in regulatory approval and unnecessary expenditure
associated with excessive duplication of clinical trials in countries they
intend to market. Unlike the regulation and adoption of new drugs
and vaccines, global governance and oversight to ensure quality and
efﬁciency are lacking in diagnostics.
The barriers faced in implementing testing at the point-of-care are
often not technological, but constraints inherent in the health care
system. To implement a successful POC diagnostics programme, the
engagement of policy makers, stakeholders and partners to ensure
buy-in and align necessary resources is a critical ﬁrst step. Training
and certiﬁcation of vast number of health care providers to use POC
diagnostics, and ensuring an effective supply chain for tests and drugs
across the country present an enormous challenge to health systems
that are already suffering from a critical shortage of human resources.
Quality assurance systems, that include providing proﬁciency testing,
sites visits, and corrective action, are essential to ensure that accurate
results are being used to guide treatment decisions, and to ensure that
control strategies are based on accurate surveillance data. Studies have
shown that deployment of POC diagnostics can be an opportunity to
improve health outcomes and strengthen health systems [29–31].
Overcoming challenges will in turn motivate health care workers and
increase capacity and efﬁciency to test and treat appropriately. RDT
introduction and implementation must be culturally sensitive and
accompanied by an inter-connected system to monitor the necessary
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processes. Another key barrier to the appropriate use of POC diagnostics
is the need to train clinicians to create a demand for them and then use
the test results to effectively manage the patients. Improving the
laboratory-clinician interface is an important but often neglected aspect
of testing introduction.
6. The way forward
Appropriate diagnostics to monitor disease trends and assess the
impact of interventions are essential for guiding treatment strategies
for NTDs at different thresholds of control, interruption of transmission,
elimination and post-elimination surveillance.
New sample in-answer out nucleic acid ampliﬁcation technologies
offer improved performance over antigen detection POCTs and the
potential to test for multiple pathogens using a single specimen. Recent
technical advances have led to improved diagnostic tests for NTDs,
which are sensitive, speciﬁc, able to diagnose multiple infections using
a single specimen, and can be used at the point of care. Since there is
extensive geographical overlap between different NTDs targeted by
MDA,multiplex surveillance platforms are likely to prove cost-effective.
Rapid deployment of these new technologies for the control and
elimination of NTDs can present multiple challenges on fragile health
systems, including quality assurance and stockout of supplies needed
for testing and treatment. Connectivity solutions linking data from
diagnostic laboratories and POC test readers/devices provide opportuni-
ties for automated surveillance systems to make health systems more
efﬁcient, improving patient outcomes and assessing impact of interven-
tions in real time. New models of public–private product development
partnerships are critical in leveraging diagnostic innovation in other
priority area for better diagnosis, control and elimination of NTDs.
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